About Element Genomics
Element Genomics is a company based in Durham (United States) founded in 2015 was acquired by UCB in April 2018. Element Genomics has raised $4.85 million across 1 funding round from investors including UCB. Element Genomics operates in a competitive market with competitors including Beam Therapeutics, eGenesis, Korro Bio, Novogene Corporation and Metagenomi, among others.
- Headquarter Durham, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
- Legal Name Element Genomics, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Element Genomics
Element Genomics has successfully raised a total of $4.85M through 1 strategic funding round. The most recent funding activity was a Series A round of $4.85 million completed in November 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Element Genomics
Element Genomics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include UCB.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Therapies for immunological and neurological disorders are developed.
|
Locked | Locked | Locked |
Investor details for Element Genomics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Element Genomics
Investment portfolio details for Element Genomics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Element Genomics
Detailed financials for Element Genomics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Element Genomics Comparisons
Peer comparison for Element Genomics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Element Genomics
Element Genomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Beam Therapeutics, eGenesis, Korro Bio, Novogene Corporation and Metagenomi, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of gene therapy using CRISPR base editing to treat diseases
|
|
| Locked | Locked | Locked |
Gene transplantation platform for humanizing pig cells is developed.
|
|
| Locked | Locked | Locked |
RNA-editing technologies are provided for precision medicine applications.
|
|
| Locked | Locked | Locked |
Genomic services and solutions with NGS expertise are provided.
|
|
| Locked | Locked | Locked |
Next-generation gene editing tools are developed for drug enhancement.
|
|
| Locked | Locked | Locked |
Genetic therapies for diseases are developed using prime editing technology.
|
Detailed competitors of Element Genomics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Element Genomics
Complete news archive for Element Genomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Element Genomics
Element Genomics was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Element Genomics is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
Element Genomics is a funded company, having raised a total of $4.85M across 1 funding round to date.
Element Genomics was founded in 2015 in Durham, United States, within the biotechnology sector. An epigenomic editing platform is developed in collaboration with Duke University to characterize the non-coding genome and map gene function and regulation. Operations center on identifying new drug targets, with emphasis placed on neurology and immunology therapeutic areas. The companys domain is elementgenomics.com.
Element Genomics's top competitors include eGenesis, Tessera Therapeutics and Novogene Corporation.
Element Genomics has 1 investor. Key investors include UCB.